Dr. Michelle Lynn Dallapiazza, MD

Dr. Dallapiazza practices at Howard Brown Health 63rd St. in Chicago, Illinois.

Dr. Dallapiazza's NPI, 1871656215, was assigned on December 18, 2006. Dr. Dallapiazza graduated from University of Pittsburgh School of Medicine in 2006. Dr. Dallapiazza holds Illinois license 036.171854.

Dr. Dallapiazza's primary practice is Howard Brown Health 63rd St., at 641 W 63rd Street, Chicago, IL 60621. The practice phone is (773) 388-1600.

Dr. Dallapiazza's primary practice is Howard Brown Health 63rd St. in Chicago, Illinois. The medical group on file is Howard Brown Health. Dmand AI also links Dr. Dallapiazza to 1 more group practice or clinic and 1 medical group, each named with a free account. Dr. Dallapiazza's employer is on file too: a community health center (fqhc).

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dallapiazza practices, 2 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Dallapiazza's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dmand AI has Dr. Dallapiazza's licenses on file in 3 states: Illinois, New Jersey and New York.

CMS data shows 59 Medicare services from Dr. Dallapiazza across 2 procedure codes in 2024, for 32 Medicare patients. Medicare paid $4,521 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 32 Medicare patients who saw Dr. Dallapiazza in 2024. The largest group is under 65, with 11 patients. 75% of them have high blood pressure, and 66% have high cholesterol. 50% are also on Medicaid. Their average risk score is 3.77, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dallapiazza's median patient age at 35, with 49% women.

In 2024, Dr. Dallapiazza wrote 2,086 Medicare Part D claims for 106 patients. 68% of them were for generic drugs. CMS names the drug for 1,637 of them, across 58 drugs with 11 or more claims each, at $1,436,999 in total drug cost. In 2023, CMS named 1,791 claims across 62 drugs.

Dr. Dallapiazza accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 13 papers to Dr. Dallapiazza, published from 2015 to 2024. 2020 was the busiest year, with 2. The most frequent topics are COVID-19, HIV Infections and Anti-HIV Agents. Dr. Dallapiazza's most frequent co-authors are Vincent Charles Marconi, MD, Charurut Somboonwit, MD and Judith Ann Aberg, MD.

CMS Open Payments shows 36 general payments to Dr. Dallapiazza from 8 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. ViiV Healthcare Company paid the most, $424.

Dr. Dallapiazza graduated from University of Pittsburgh School of Medicine in 2006.